The U.K. Approves Copaxone (Glatiramer Acetate) For Relapsing-remitting Multiple Sclerosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




The U.K. Approves Copaxone (Glatiramer Acetate) For Relapsing-remitting Multiple Sclerosis

JERUSALEM, ISRAEL -- August 14, 2000 -- Teva Pharmaceutical Industries, Ltd., announced that Copaxone® (glatiramer acetate for injection) was approved for marketing in the U.K. This is the first approval in a major European market and enables Teva to file for approval all over the E.U. under the mutual recognition procedure.

Teva plans to launch Copaxone in the U.K. market in the beginning of the fourth quarter of this year.

Copaxone is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis.

Eli Hurvitz, President and Chief Executive Officer commented: "We are excited to have received this approval and even more with the opportunity it represents for the rest of the European market."

Teva is currently preparing the filing under the European Mutual Recognition Procedure to make Copaxone available in the remainder of the European Union. The U.K. has agreed to act as the reference member state. The successful completion of this procedure is expected to enable Teva to launch Copaxone in the E.U. around mid 2001.

Related Links: Copaxone (glatiramer acetate) and Teva Pharmaceutical Industries, Ltd.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities